JIANGXI FUSHINE PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.19 CNY | -5.43% |
|
-7.14% | -12.50% |
| Feb. 19 | Fushine Pharma's Unit Gets Nod for Tazobactam Sodium | MT |
| 2023 | Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding | CI |
| Sales 2021 | 1.43B 198M | Sales 2022 | 1.65B 228M | Capitalization | 7.11B 982M |
|---|---|---|---|---|---|
| Net income 2021 | 48M 6.63M | Net income 2022 | -141M -19.48M | EV / Sales 2021 | 5.92 x |
| Net cash position 2021 | 422M 58.24M | Net Debt 2022 | 390M 53.88M | EV / Sales 2022 | 4.55 x |
| P/E ratio 2021 |
181
x | P/E ratio 2022 |
-50.8
x | Employees | 2,179 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 70.76% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.43% | ||
| 1 week | -7.14% | ||
| Current month | -12.03% | ||
| 1 month | -6.61% | ||
| 3 months | -8.08% | ||
| 6 months | -30.48% | ||
| Current year | -12.50% |
1 week
8.11
9.15
1 month
8.119.80
Current year
5.629.80
1 year
5.6214.33
3 years
5.6229.40
5 years
5.6229.40
10 years
3.2929.40
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 12-07-31 |
Guang Yang
DFI | Director of Finance/CFO | 37 | 08-12-31 |
Rong Wu Cheng
BRD | Director/Board Member | 55 | 04-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Li
BRD | Director/Board Member | 67 | 15-06-30 |
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 12-07-31 |
Wei Dong
BRD | Director/Board Member | 46 | 12-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 8.19 | -5.43% | 6,783,925 |
| 24-04-12 | 8.66 | -1.59% | 3,284,981 |
| 24-04-11 | 8.8 | -1.01% | 2,906,100 |
| 24-04-10 | 8.89 | -2.74% | 3,774,518 |
| 24-04-09 | 9.14 | +3.63% | 3,979,728 |
End-of-day quote Shenzhen S.E., April 14, 2024
More quotes
Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.50% | 609M | |
| +28.79% | 676B | |
| +23.99% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +3.17% | 213B | |
| +0.45% | 207B | |
| -8.63% | 199B | |
| -10.00% | 147B |
- Stock Market
- Equities
- 300497 Stock
